ExodusPoint Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

ExodusPoint Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-26,329	Closed	-$294K	–	1620
2023 Q3	$294K	Buy	+26,329	New	+$424K	﹤0.01%	1422
2023 Q2	–	Sell	-20,147	Closed	-$815K	–	1952
2023 Q1	$815K	Buy	+20,147	New	+$962K	0.01%	1208
2022 Q4	–	Sell	-12,804	Closed	-$664K	–	1755
2022 Q3	$664K	Buy	+12,804	New	+$748K	0.01%	1268
2022 Q1	–	Sell	-5,568	Closed	-$416K	–	2311
2021 Q4	$416K	Buy	+5,568	New	+$437K	﹤0.01%	1508
2020 Q4	–	Sell	-6,292	Closed	-$288K	–	2062
2020 Q3	$288K	Buy	+6,292	New	+$305K	0.01%	1309

Other funds holding ENTA

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ExodusPoint Capital Management's ENTA Position: Q4 2023 in Review

ExodusPoint Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q4 2023, closing a stake of 26,329 shares — an estimated $294K sold.

ExodusPoint Capital Management first reported a position in ENTA in Q3 2020 and held it in 5 quarters. The position peaked at $815K in Q1 2023. 105 funds tracked by Wall St. Rank hold ENTA as of Q4 2023.

ExodusPoint Capital Management reported no remaining Enanta Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
ExodusPoint Capital Management sold 26,329 Enanta Pharmaceuticals shares in Q4 2023, an estimated $294K.
ExodusPoint Capital Management first reported a position in Enanta Pharmaceuticals in Q3 2020 and held it in 5 quarters.
ExodusPoint Capital Management's Enanta Pharmaceuticals position peaked at $815K in Q1 2023.
105 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2023.

Based on ExodusPoint Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.